Literature DB >> 19116234

Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: implications for radioiodine treatment.

Stéphane Bonnet1, Dana Hartl, Sophie Leboulleux, Eric Baudin, Jean D Lumbroso, Abir Al Ghuzlan, Linda Chami, Martin Schlumberger, Jean Paul Travagli.   

Abstract

OBJECTIVE: Prophylactic neck dissection for small papillary carcinoma remains controversial. Radioiodine ablation is not recommended for tumors less than 10 mm and depends on various factors for tumors between 10 and 20 mm. The aim was to determine the effect of lymph node (LN) staging on the indication for treatment with radioiodine. PATIENTS AND METHODS: We conducted a retrospective study of 115 patients presenting with papillary thyroid carcinoma less than 2 cm without ultrasonographically detectable cervical LN treated by total thyroidectomy and complete selective dissection of the central and lateral compartment. Radioiodine treatment was based on definitive pathology (tumor and LN). Follow-up was based on neck ultrasound and thyroglobulin levels.
RESULTS: LN were found for 41.7% of cases. Radioiodine was not used for 42% of patients with tumors less than 20 mm and no metastatic LN. Fifty-eight percent of patients were treated with radioiodine due to LN metastasis, extracapsular thyroid invasion, or unfavorable histological subtype. LN status affected the indication for radioiodine in 30.5% of cases classified as T1, 12 cases with tumors less than 10 mm but with LN metastases (who received radioiodine), and 13 cases with tumors between 10 and 20 mm but without LN metastases (who did not receive radioiodine). Definitive vocal fold paralysis and hypoparathyroidism each occurred in 0.9% of cases. At 1 yr, ultrasound was normal in all patients, and recombinant human TSH-stimulated thyroglobulin was undetectable for 97% of the patients.
CONCLUSION: Precise LN staging by prophylactic neck dissection for tumors initially staged T1N0 modified the indication for radioiodine ablation for 30% of patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19116234     DOI: 10.1210/jc.2008-1931

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  73 in total

1.  Pattern of initial metastasis in the cervical lymph node from papillary thyroid carcinoma.

Authors:  Naoyoshi Onoda; Tetsuro Ishikawa; Hidemi Kawajiri; Tsutomu Takashima; Kosei Hirakawa
Journal:  Surg Today       Date:  2012-06-26       Impact factor: 2.549

2.  Managing patients with a preoperative diagnosis of AJCC/UICC stage I (T1N0M0) papillary thyroid carcinoma: East versus West, whose policy is best?

Authors:  Ian D Hay
Journal:  World J Surg       Date:  2010-06       Impact factor: 3.352

3.  Evaluation of postoperative radioactive iodine scans in patients who underwent prophylactic central lymph node dissection.

Authors:  Amanda M Laird; Paul G Gauger; Barbra S Miller; Gerard M Doherty
Journal:  World J Surg       Date:  2012-06       Impact factor: 3.352

Review 4.  Controversies in the Management of Low-Risk Differentiated Thyroid Cancer.

Authors:  Megan R Haymart; Nazanene H Esfandiari; Michael T Stang; Julia Ann Sosa
Journal:  Endocr Rev       Date:  2017-08-01       Impact factor: 19.871

5.  Occult papillary thyroid microcarcinoma manifesting only as a symptomatic lateral cervical mass: report of a case.

Authors:  Mariano Batori; Antonio Zullino; Raoul Pipino; Chatelou Eleni
Journal:  Surg Today       Date:  2012-04-26       Impact factor: 2.549

Review 6.  Prophylactic central neck disection in papillary thyroid cancer: a consensus report of the European Society of Endocrine Surgeons (ESES).

Authors:  Juan J Sancho; Thomas W Jay Lennard; Ivan Paunovic; Frédéric Triponez; Antonio Sitges-Serra
Journal:  Langenbecks Arch Surg       Date:  2013-12-19       Impact factor: 3.445

7.  Disease severity and radioactive iodine use for thyroid cancer.

Authors:  M R Haymart; D G Muenz; A K Stewart; J J Griggs; M Banerjee
Journal:  J Clin Endocrinol Metab       Date:  2013-01-15       Impact factor: 5.958

8.  Risks and adequacy of an optimized surgical approach to the primary surgical management of papillary thyroid carcinoma treated during 1999-2006.

Authors:  Clive S Grant; John M Stulak; Geoffrey B Thompson; Melanie L Richards; Carl C Reading; Ian D Hay
Journal:  World J Surg       Date:  2010-06       Impact factor: 3.352

Review 9.  German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors.

Authors:  Henning Dralle; Thomas J Musholt; Jochen Schabram; Thomas Steinmüller; Andreja Frilling; Dietmar Simon; Peter E Goretzki; Bruno Niederle; Christian Scheuba; Thomas Clerici; Michael Hermann; Jochen Kußmann; Kerstin Lorenz; Christoph Nies; Peter Schabram; Arnold Trupka; Andreas Zielke; Wolfram Karges; Markus Luster; Kurt W Schmid; Dirk Vordermark; Hans-Joachim Schmoll; Reinhard Mühlenberg; Otmar Schober; Harald Rimmele; Andreas Machens
Journal:  Langenbecks Arch Surg       Date:  2013-03-03       Impact factor: 3.445

10.  Should patients with remnants from thyroid microcarcinoma really not be treated with iodine-131 ablation?

Authors:  Rosj Gallicchio; Sabrina Giacomobono; Daniela Capacchione; Anna Nardelli; Francesco Barbato; Antonio Nappi; Teresa Pellegrino; Giovanni Storto
Journal:  Endocrine       Date:  2013-03-28       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.